行情

MYOK

MYOK

MyoKardia
NASDAQ

实时行情|Nasdaq Last Sale

54.81
+1.51
+2.83%
盘后: 54.81 0 0.00% 16:00 10/15 EDT
开盘
53.56
昨收
53.30
最高
55.35
最低
53.27
成交量
23.35万
成交额
--
52周最高
64.40
52周最低
39.01
市值
25.28亿
市盈率(TTM)
-21.6060
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MYOK 新闻

  • 高盛CEO:Apple Card是"有史以来最成功信用卡发行"
  • 新浪美股.1小时前
  • 联储贴现率决策内部分歧加剧 对立双方接近"五五开"
  • 新浪美股.1小时前
  • 巴菲特向美联储寻求批准 将增持美国银行股份超过10%
  • 新浪美股.1小时前
  • 邓普顿基金明星经理失手 旗舰债基三个月亏30亿美元
  • 新浪美股.1小时前

更多

所属板块

生物技术和医学研究
+1.98%
制药与医学研究
+1.25%

热门股票

名称
价格
涨跌幅

MYOK 简况

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
展开

Webull提供Myokardia Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。